ER Editor: We’re asking what is going on in Denmark as it has recently come to the forefront as being a partner with the World Economic Forum to accelerate the Great Reset, and has attempted to pass a tyrannical ‘epidemic law’ obliging mandatory vaccination that its citizens are having to fight hard against. Now this, where a public institute passed on blood samples of over 250 women to an American company owned by none other than Zuckerberg. As to the nature of this test, we found this at a site called Engineers Ireland, where no mention is made of unethical use of study participants’ blood:
Measuring RNA fragments in a pregnant woman’s blood gives a reliable estimate of the baby’s due date and can predict if the baby will arrive prematurely, a Stanford-led team has shown. A new blood test for pregnant women detects, with 75 to 80 per cent accuracy, whether their pregnancies will end in premature birth. The technique can also be used to estimate a foetus’s gestational age — or the mother’s due date — as reliably as and less expensively than ultrasound.
Tests could help reduce problems related to premature birth
Developed by a team of scientists led by researchers at Stanford University, the tests could help reduce problems related to premature birth, which affects 15 million infants worldwide each year. Until now, doctors have lacked a reliable way to predict whether pregnancies will end prematurely, and have struggled to accurately predict delivery dates for all types of pregnancies, especially in low-resource settings. The blood tests are described in a paper published recently in ‘Science’. Stephen Quake, PhD, professor of bioengineering and of applied physics at Stanford, shares senior authorship with Mads Melbye, MD, visiting professor of medicine. The lead authors are former Stanford postdoctoral scholar Thuy Ngo, PhD, and Stanford graduate student Mira Moufarrej. “This work is the result of a fantastic collaboration between researchers around the world,” said Quake, who is also the Lee Otterson Professor in the School of Engineering. “We have worked closely with the team at the Stanford March of Dimes Prematurity Research Center, and the research involved collaborations with scientists in Denmark, Pennsylvania and Alabama. It’s really team science at its finest.”
The tests measure the activity of maternal, placental and foetal genes by assessing maternal blood levels of cell-free RNA, tiny bits of the messenger molecule that carry the body’s genetic instructions to its protein-making factories. The team used blood samples collected during pregnancy to identify which genes gave reliable signals about gestational age and prematurity risk. “We found that a handful of genes are very highly predictive of which women are at risk for pre-term delivery,” said Melbye, who is also president and CEO of the Statens Serum Institute in Copenhagen. “I’ve spent a lot of time over the years working to understand pre-term delivery. This is the first real, significant scientific progress on this problem in a long time.”
********
Business venture linked to Mark Zuckerberg used blood samples from pregnant women without their consent, Danish media reports
RT
Blood samples from Danish women participating in a public research project ended up in the hands of an organization founded by Facebook CEO Mark Zuckerberg, raising numerous red flags, local media reports.
When 263 mothers-to-be provided weekly blood samples to Denmark’s State Serum Institute (SSI) to help researchers learn more about the body during pregnancy, they weren’t told that their blood was also being used for a private business venture connected to Zuckerberg, according to Danish Radio.
Blood samples from the research project, which began in 2014, were sent to Stanford University, a private research institution in California, where they were used to develop a blood test to detect premature birth. The then-director of SSI, Mads Melbye, together with his American research colleagues, started a private company and in 2018 entered into a business agreement with the Chan Zuckerberg Biohub, founded and named after Zuckerberg and his wife, Chan.
The Zuckerberg-linked research center patented the blood test and has “gained the most control over [it],” Danish Radio reported. The company is also allegedly in charge of commercializing the test.
An expert in contract law from Copenhagen Business School told the station that the collaboration agreement between SSI and Chan Zuckerberg Biohub was a “bad agreement for Denmark.”
The development of the potentially lucrative test was also a bad deal for the unwitting women involved. They were never informed that their blood would be transported to the United States for analysis, and were also unaware that it would be used to pursue commercial interests.
“I feel that my trust and my good intentions have been abused,” one of the women told the Danish outlet.
Although the original SSI project was approved by Denmark’s Science Ethics Committee, a government review concluded that sending the blood samples to the US without clear consent violated data processing rules.
Melbye resigned from SSI this summer after facing scrutiny over his role in the scheme, but has denied any wrongdoing. SSI has apologized for not properly informing the women about the commercial aspects of the project. It doesn’t appear that Chan Zuckerberg Biohub has commented on the Danish report.
Source
********
Zuckerberg’s Biohub involved in commercially exploiting data from unsuspecting pregnant Danish women
Pregnant Danish women participated in a public research project giving blood samples at the State Serum Institute (SSI) every week. They have now discovered that they were actually unwittingly contributing to an American business enterprise in which Facebook CEO and billionaire Mark Zuckerberg is involved.
FREEWEST MEDIA
COPENHAGEN These Danish participants in a medical research project were never informed of the commercial interests: The project is likely to become a huge international success. The data protection violation of some 263 women has been called a “bad deal for Denmark”.
Danish Radio reported that blood samples were taken from the participants for the duration of their pregnancy to track neurotransmitters. The samples were the basis of a blood test designed to predict premature birth, now tipped to become a worldwide commercial success.
The American research center, the Chan Zuckerberg Biohub, conducting the studies was founded by Zuckerberg, currently the co-owner of the lucrative invention. The participants, however, were never informed of the commercial interests linked to the research project at Stanford University.
The research project had been approved by a Danish Science Ethics Committee, but the SSI was never notified of the commercial interests of the project, launched by a Dane, Mads Melbye, in the US.
According to Kent Kristensen, associate professor of health law at the University of Southern Denmark, there had been no data processor agreement, and the samples were transferred illegally in violation of the rules on data protection.
************
Source
••••
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
••••
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
••••
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
••••
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
